Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Healthtrust
Cantor Fitzgerald
Mallinckrodt
Argus Health
Boehringer Ingelheim
Baxter
Julphar
US Army
Express Scripts

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,229,640

« Back to Dashboard

Which drugs does patent 7,229,640 protect, and when does it expire?

Patent 7,229,640 protects PAXIL CR and is included in one NDA.

Protection for PAXIL CR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-five patent family members in forty countries.
Summary for Patent: 7,229,640
Title:Paroxetine controlled release compositions
Abstract:A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.
Inventor(s): Leonard; Graham Stanley (St. Albans, GB), Elder; David Philip (Hertford, GB)
Assignee: SmithKline Beecham p.l.c. (Brentford, GB)
Application Number:10/024,858
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use;

Drugs Protected by US Patent 7,229,640

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-001 Feb 16, 1999 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-002 Feb 16, 1999 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Apotex Technologies PAXIL CR paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 020936-003 Dec 6, 2000 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,229,640

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9514842Jul 20, 1995

Non-Orange Book US Patents Family Members for Patent 7,229,640

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,548,084 Controlled release compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,229,640

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Czech Republic 9800183 ➤ Subscribe
China 1282456 ➤ Subscribe
China 1117567 ➤ Subscribe
China 1515257 ➤ Subscribe
Canada 2445678 ➤ Subscribe
China 1195986 ➤ Subscribe
Germany 69630603 ➤ Subscribe
Czech Republic 294110 ➤ Subscribe
Cyprus 2408 ➤ Subscribe
Canada 2227298 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Farmers Insurance
Citi
US Department of Justice
UBS
Covington
Novartis
Healthtrust
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot